There is concern that the White House is considering imposing further limits on research by Chinese citizens in the United States, saying that “scientific progress depends on openness, transparency, and the free flow of ideas”
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
U.S. regulators approved Novartis’ cell therapy Kymriah for the treatment of patients with a second type of blood cancer.
Thermo Fisher Scientific has signed agreements with Takeda Pharmaceuticals and Daiichi Sanyo that will enable the Japanese firms to leverage Thermo Fisher’s FDA approved Oncomine Dx Target Test for their clinical trials and drug development programs.
The Scripps Translational Science Institute has received over $34 million in renewed funding from the National Institutes of Health’s National Center for Advancing Translational Sciences to advance medical research and clinical care through genomic and digital technologies.
Gilead Sciences will partner with Google Parent Alphabet’s Verily Life Sciences over the next three years, applying Verily’s Immunoscape platform to better understand the immunological basis of three common diseases.
Novartis’ entry into the digital technology market intensifies with the recent launch of its mobile-phone based app to help collect data from eye disease studies.
AI genomics company Freenome has announced a partnership with proteomics company Biognosys, to enhance its broad-signal approach to early-cancer detection and precision oncology.
It’s been a busy time for R&D execs, as they continue to be snapped up by rival pharma companies, proving that it’s a competitive time out there at the top.
Illumina’s new Bay Area campus boasts connectivity, collaboration, and innovation, but some are unsure whether it will be able to draw in the appeal from workers.
Allergan has retracted its interest in pursuing a deal for Shire, only a mere few hours after originally saying so.